Am J Psychiatry 1981; 138:20-24
Copyright © 1981 by American Psychiatric Association
Amoxapine and imipramine in the treatment of depressed outpatients: a controlled study
K Rickels, WG Case, J Werblowsky, I Csanalosi, A Schless and CC Weise
In a double-blind, controlled study 158 outpatients with unipolar
depression were treated for six weeks with amoxapine, imipramine, or
placebo to assess the antidepressant effects of the new dibenzooxazepine
compound, amoxapine. Forty-five amoxapine, 43 imipramine, and 27 placebo
patients completed at least four weeks of treatment. Active drugs produced
significantly more improvement at treatment endpoint, according to several
physician-rated measures, but patient-rated measures failed to
differentiate among treatments. Both active drugs at daily doses up to 200
mg produced an equal amount of moderate and marked global improvement, and
both produced significantly more side effects than did placebo.
